REG - GSK PLC - Director/PDMR Shareholding

GSKAnnouncement

11/02/2026 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260211:nRSK6489Sa&default-theme=true

RNS Number : 6489S  GSK PLC  11 February 2026

GSK plc (the 'Company')

Transaction notification

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Luke Miels
 b)  Position/status                          Chief Executive Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63

 b)  Nature of the transaction                Following the vesting on 10 February 2026 of the final 25% of an award made on
                                              10 February 2021 under the GlaxoSmithKline Deferred Investment Award
                                              Programme, Luke Miels will receive a cash payment of £541,555.40 less
                                              applicable tax withholding in respect of 24,979.493 notional Ordinary Shares.
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.68                24,979.493

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-02-10
 f)  Place of the transaction                 N/A

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Regis Simard
 b)  Position/status                          President, Global Supply Chain
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63

 b)  Nature of the transaction                Following the vesting on 10 February 2026 of the final 25% of an award made on
                                              10 February 2021 under the GlaxoSmithKline Deferred Investment Award
                                              Programme, Regis Simard will receive a cash payment of £270,777.70 less
                                              applicable tax withholding in respect of 12,489.746 notional Ordinary Shares.
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.68                12,489.746

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-02-10
 f)  Place of the transaction                 N/A

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Deborah Waterhouse
 b)  Position/status                          CEO, ViiV Healthcare and President, Global Health, GSK
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63

 b)  Nature of the transaction                Following the vesting on 10 February 2026 of the final 25% of an award made on
                                              10 February 2021 under the GlaxoSmithKline Deferred Investment Award
                                              Programme, Deborah Waterhouse will receive a cash payment of £541,555.40 less
                                              applicable tax withholding in respect of 24,979.493 notional Ordinary Shares.
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.68                24,979.493

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-02-10
 f)  Place of the transaction                 N/A

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com/) .

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSFIFIFEMSEEE



            Copyright 2019 Regulatory News Service, all rights reserved